Treatment and Prognosis of Patients With Chronic HBV Infection

Hepatitis B virus (HBV) infection is a major global health issue with 257 million chronically infected individuals. Of note, China has the largest population accounting for one third of the world's infected population. Approximately, about 300 000 people die each year due to the consequences of HBV. In 2016, the World Health Organization (WHO) proposed the goal for elimination of hepatitis B as public health threat by 2030 and China will be a major contributor towards this global goal. Currently, two approved therapeutic strategies are available including pegylated interferon (IFN) or nucleos (t) ide analogues (NA), which could suppress HBV replication and slow disease progression. Here, investigators hope to launch a cohort study to reveal the clinical features relating to therapeutic efficacy of antiviral therapy and the prognosis of patients with differential therapeutic strategies.

NCT Number	NCT05392387
Lead Sponsor	Xiangya Hospital of Central South University
Conditions	Hepatitis B Virus Infection
Enrollment	500 participants
Start Date	2021-10-25
Primary Completion	2024-10-25 (estimated)
Study Completion	2026-10-25 (estimated)
Updated on ClinicalTrials.gov	2022-05-26